Novel Protein Technology Opens Doors to Danish Biotech Company

In this exclusive interview, Fintan Walton talks to Johanna Holldack, CEO of Borean Pharma. The conversation begins with a discussion on the unique aspects of Borean's proprietary technology, including its scaffold library, which is derived from a human protein, and whose compounds possess features that facilitate the process of their development. Johanna then discusses Borean's current strategy of developing its lead molecules for entry into clinical trials in 2009. The 2006 product acquisition deal between Borean and F. Hoffmann-La Roche is also discussed, and Johanna explains why Roche may have been interested in acquiring one of Borean's lead candidates. The interview then turns towards the state of the biotech industry in Denmark, and how this is backed by innovative research, especially in the field of protein engineering, that is taking place in the Denmark's research institutes and universities. The importance of international investors to small biotech companies is covered, and the interview concludes with Johanna's speculation on whether the company will undergo an IPO or an acquisition.

Pharma Television | July 31, 2007

Tags:. .acquiring. .acquisition. .aspects. .begins. .between